Oxford and AstraZeneca developing Omicron-targeted version of vaccine

Oxford University and AstraZeneca have begun work on an Omicron-targeted version of their coronavirus vaccine, joining the ranks of their peers who are studying the potential for adapting formulations of their shots in case they become necessary to tackle the variant.

When asked about Omicron, Sandy Douglas, a research group leader at Oxford, told the Financial Times: “Like with many previous variants of concern, and together with our partners AstraZeneca, we have taken preliminary steps in producing an updated vaccine in case it is needed.”